Repertoire Immune Medicines added Eli Lilly to its roster of pharma partners in a multimarket tolerizing‑therapy collaboration, securing a major upfront and milestone package that values the program in the high hundreds of millions to billions. The deal builds on Repertoire’s Decode immune‑profiling platform, which the company has previously licensed to Bristol Myers Squibb, Genentech and others. Repertoire said the Lilly agreement validates its approach to identifying tolerogenic targets for autoimmune diseases. The alliance maps to a broader industry tilt toward synthetic immune‑modulation and tolerizing vaccines. For Repertoire, the funding accelerates preclinical and translational work and supports platform scale-up; for Lilly it expands a pipeline of immune‑modifying assets beyond conventional biologics. The deal underscores continued appetite from major pharma to buy synthetic‑biology and immune‑profiling capabilities from startups.